Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EPS (Basic): 2016-2025

Historic EPS (Basic) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$0.45.

  • Rocket Pharmaceuticals' EPS (Basic) rose 36.62% to -$0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.25, marking a year-over-year increase of 17.58%. This contributed to the annual value of -$2.73 for FY2024, which is 6.51% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.45 for Q3 2025, which was up 27.42% from -$0.62 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' EPS (Basic) ranged from a high of -$0.45 in Q3 2025 and a low of -$0.89 during Q4 2022.
  • For the 3-year period, Rocket Pharmaceuticals' EPS (Basic) averaged around -$0.66, with its median value being -$0.66 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 37.61% in 2021, then tumbled by 50.91% in 2022.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' EPS (Basic) stood at -$0.68 in 2021, then slumped by 30.88% to -$0.89 in 2022, then skyrocketed by 30.34% to -$0.62 in 2023, then remained steady at -$0.62 in 2024, then skyrocketed by 36.62% to -$0.45 in 2025.
  • Its EPS (Basic) stands at -$0.45 for Q3 2025, versus -$0.62 for Q2 2025 and -$0.56 for Q1 2025.